Patrick Soon Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared Bradon Clark‘s post, adding:
“Thanks for sharing Brandon.
Your chart helps explain the Nant Cancer Protocol and the Bioshield platform. It highlights the importance of protecting your immune system while receiving today’s standard of care. So I will attempt to describe for all those that would like to understand what is happening per your chart and the why and how we do what we do .
The WHY: Protecting your immune system while patients receive chemo radiation and checkpoints matters because your NK cells and T cells are key cancer killer cells needed to fight cancer. These treatments all unfortunately result in the loss of NK and T cells. If they fall to low levels below 1000 after chemo as yours did, the killer T cells are too few ( called lymphopenia) in the tumor micro environment to fight the cancer and cancer cells grows. This loss of cancer killer cells ( lymphocytes) is even worse with radiation.
This does not mean we don’t use chemo or radiation but we synergize with these standards of care by protecting your immune system at the same time while killing the tumor cells.. So by maintaining what we call ‘immune competence’ and allowing the chemo ( at a lower dose) to smoke out the tumor, multiple points of attack occur. And the tumors shrink .. with the goal of teaching your T cells to remember ( Memory T cells).
Now the HOW: the realization that Tcells and NK cells have a receptor on them called IL15 and that if this receptor is activated these cancer killer cells grow and become supercharged.
ANKTIVA IS THE KEY THAT UNLOCKS THAT RECEPTOR.
is designed to lock onto the IL15 receptor of your NK and T cells and grow them in your body and measure that growth in your blood with a simple test called ‘ absolute lymphocyte count’ or ALC for short. So your graph shows how your NK cells and T cells grow by measuring the ALC levels .. from 800 ( lymphopenia) when you received chemo to over 2000 when you received Anktiva together with standard of care.. to recover your lymphocytes and restore Immune Competence. And so your tumor shrinks.
No magic. Just an enlightened way to treat patients with cancer. NK and T cells matter Immune competence matters A new paradigm that I hope this example helps my doctor colleagues understand the next generation of immunotherapy is here.
Happy New Year! A town hall next year to share with patients and doctors alike.”
Quoting Bradon Clark‘s post:
“A very informative chart no thanks to Chiayu Chen for doing the leg work on my labs. Thank you Dr Chen. I started a low dose chemo, capecetapine, prior to me starting the BIOSHIELD ANKTIVA.
The low dose of chemo is used to educate my T and NK cells to target!! Smoke that tumor out! Then my T cells and Natural Killer cells attack! All perfectly represented in my labs… my ALC. absolute lymphocyte count. My Progress is promising. First ever tumor shrinkage, and stable. Notice after starting chemo my ALC plummeted, once on ANKTIVA.. skyrockets while I’m on chemo. Remarkable!!”
More posts featuring Patrick Soon Shiong.